Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liora M Schultz

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Blood Advances|January 22, 2025
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug eraLianna J Marks, Victor Ritter, Jennifer E Agrusa, et al.
Blood|September 9, 2021
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemiaJenna Rossoff, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Blood Advances|January 22, 2025
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug eraLianna J Marks, Victor Ritter, Jennifer E Agrusa, et al.
Blood|September 9, 2021
Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemiaJenna Rossoff, Christina Baggott, Snehit Prabhu, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
Leukemia|March 16, 2024
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b resultsLiora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, et al.
Pageof 4